Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. [electronic resource]
Producer: 20150723Description: 1433-41 p. digitalISSN:- 1434-9949
- Adalimumab
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antirheumatic Agents -- adverse effects
- Arthritis, Juvenile -- blood
- Biomarkers -- blood
- C-Reactive Protein -- metabolism
- Child, Preschool
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Europe
- Female
- Humans
- International Cooperation
- Male
- Methotrexate -- therapeutic use
- Treatment Outcome
- United States
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.